• TRM (USD/COP)COP 3,461.92 +1.37% +COP 46.82Colombia's official exchange rate (Financial Superintendence), valid Nov 21 to Nov 23
  • EuroCOP 3,804.64 +1.37% +COP 51.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
  • Mexican pesoCOP 181.56 +1.37% +COP 2.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote

Johnson & Johnson reports 75% tumor response with JNJ-6143 in Phase 1 prostate cancer trial

FinanceInternationalRevista ADVFN45 s readAI summary
Image: Revista ADVFN

Johnson & Johnson (NYSE:JNJ) presented Phase 1 results for JNJ-6143, an experimental oral treatment for advanced prostate cancer, at the ESMO 2026 congress in Madrid. In the 50 mg group, 12 of 16 patients with measurable disease achieved a confirmed tumor response (75%), and 77% of 38 patients recorded a PSA reduction of at least 50%. The company selected that once-daily dose to continue with a Phase 2 trial in metastatic cancer. The most frequent adverse events were elevated cholesterol, nausea and high triglycerides.

In 45 seconds

  • In the 50 mg group, 12 of 16 patients with measurable disease achieved a confirmed complete or partial tumor response, a rate of 75%
  • 77% of 38 patients on that dose had a confirmed PSA reduction of at least 50%, and 48% fell by 90% or more
  • The most frequent adverse events were elevated cholesterol (18%), nausea (16%) and increased triglycerides (16%); one patient discontinued treatment
Read the full story at Revista ADVFN

IASummary generated by artificial intelligence from a story by Revista ADVFN. It may contain errors: the original source prevails.

Comments

Be respectful. Comments reported by several people are hidden until a moderator reviews them.

You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.

    Keep reading